fda compounding tirzepatide ban on compounded tirzepatide: Switch to name brand medications Important Tirzepatide Update! As the

Daniels RD, Bertke S, Dahm MM, Yiin JH, Kubale TL, Hales TR, Baris D, Zahm SH, Beaumont JJ, Waters KM, Pinkerton LE

Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery, January 2023, Preda et al

It's taught me how to stop overeating

15 reported that overexpression of Nrf2 enhanced the levels of SOD, HO-1, and NQO1 and mitigated AP in vivo and in vitro

Lyons emphasized the need for further research: To build on this progress, larger randomized controlled trials are necessary to validate these findings

The second major comparative trial recently landed in Gastroenterology TEM or ESD in Early Rectal Tumors: A Clinical & Cost-Effectiveness Analysis The MUCEM Study (Beyer-Berjot et al., Gastroenterology 2026) The largest comparison of TEM/TAMIS and ESD to date: 330 patients across 23 French expert centers, prospective multicenter design